Global Preterm Birth Diagnostic Test Kits Market Size By Type (fFN Test Kits, PAMG-1 Test Kits), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Preterm Birth Diagnostic Test Kits Market was valued at USD 1.1 billion in 2023 and is projected to reach USD 2.3 billion by 2031, growing at a CAGR of 9.4% during the forecast period from 2023 to 2031. Preterm birth, defined as delivery before 37 weeks of gestation, is a leading cause of neonatal morbidity and mortality worldwide. The growing awareness around maternal and fetal health, increasing prevalence of premature births, and the need for early and accurate diagnosis are propelling demand for diagnostic kits. Innovations in biomarkers and non-invasive testing techniques are also contributing to market growth.

Drivers:

1. Rising Global Incidence of Preterm Births:

An increasing number of premature deliveries, driven by factors like maternal age, lifestyle changes, and chronic diseases, has intensified the demand for timely and accurate diagnostic tools.

2. Advances in Biomarker-Based Testing:

Progress in molecular diagnostics, particularly the identification of specific biomarkers such as fetal fibronectin and interleukin-6, is enabling earlier detection of preterm labor risk.

3. Growing Maternal Health Awareness:

Enhanced prenatal care initiatives and education campaigns globally are encouraging early screening, driving adoption of test kits in both developed and developing regions.

Restraints:

1. Limited Accessibility in Low-Resource Settings:

Despite increasing awareness, access to reliable diagnostic test kits remains low in many parts of Africa and Southeast Asia due to cost constraints and infrastructure gaps.

2. Variability in Diagnostic Accuracy:

Differences in test sensitivity and specificity, depending on biomarkers and methods used, can lead to inconsistent results, hindering clinical confidence in some regions.

Opportunity:

1. Expansion of Point-of-Care Testing (POCT):

The rising preference for home- or clinic-based rapid tests offers strong growth potential, especially in rural or underserved areas. Innovations in compact, user-friendly kits are expected to broaden market reach.

2. Strategic Collaborations for Test Development:

Public-private partnerships focusing on maternal health and diagnostics are opening new avenues for product development and market entry in emerging economies.

Market by System Type Insights:

The biomarker-based diagnostic kits segment led the market in 2023, primarily due to their high predictive value and integration with molecular diagnostics platforms. Kits based on fetal fibronectin (fFN) dominated within this category, offering a reliable indicator for assessing the risk of preterm delivery. However, interleukin-based assays are projected to witness the fastest growth, fueled by ongoing research and clinical validation.

Market by End-use Insights:

The hospital and maternity clinic segment held the largest share in 2023, driven by the availability of skilled personnel, access to follow-up treatments, and integration with prenatal care services. Diagnostic laboratories also represented a significant segment, particularly in urban regions with established healthcare infrastructure. Meanwhile, home-based testing kits are gaining momentum due to the convenience and privacy they offer.

Market by Regional Insights:

North America dominated the global market in 2023, supported by advanced healthcare systems, high awareness levels, and early adoption of innovative diagnostic solutions. Europe followed closely, with strong growth in countries like Germany, France, and the UK. The Asia-Pacific region is projected to register the fastest CAGR through 2031, attributed to increasing healthcare investments, a high birth rate, and growing awareness about maternal-fetal complications.

Competitive Scenario:

Key players in the Global Preterm Birth Diagnostic Test Kits Market include Hologic, Inc., QIAGEN, Sera Prognostics, Inc., Abbott Laboratories, Medix Biochemica, Biosynex SA, and EKF Diagnostics. These companies are focusing on strategic collaborations, product innovation, and regulatory approvals to strengthen their global presence.

Key Market Developments:

2023: Sera Prognostics announced expanded partnerships with U.S. health networks to deploy its PreTRM® test for early risk detection of preterm birth.

2024: Hologic, Inc. introduced an updated fFN test with improved sensitivity, tailored for low-resource settings.

2025: QIAGEN unveiled a multiplex PCR-based diagnostic platform integrating maternal infection screening and preterm birth risk assessment.

Scope of Work – Global Preterm Birth Diagnostic Test Kits Market

Report Metric Details

Market Size (2023) USD 1.1 billion

Projected Market Size (2031) USD 2.3 billion

CAGR (2023–2031) 9.4%

Market Segments By System Type (Biomarker-Based, Instru